texas oncology more breakthroughs. more victories
Request an Appointment

Fort Worth Clinical Trials

Texas Oncology cancer centers in Fort Worth participate in a wide range of clinical trials and ground-breaking cancer research paving the way for new breakthroughs in cancer care. If you are a Texas Oncology patient in the Fort Worth area, you may be able to take part in these innovative clinical trials. Learn more and see a full list of current trials.

Our cancer researchers in the Fort Worth area are involved in several types of clinical trials:

  • Prevention trials focused on preventing cancer or recurrence. Trials might focus on the use of vitamins, different medications or a change in diet or exercise to determine if the risk of developing cancer is lowered.
  • Screening trials focused on identifying and detecting cancer in people who do not exhibit symptoms of cancer.
  • Diagnostic trials determining how to identify cancers using new tests. These trials often involve participants who show signs or symptoms of a particular cancer.
  • Treatment trials designed to answer questions about new treatments, such as drugs, surgical procedures, vaccines, or therapies involving current cancer patients.

Benefits and Risks of Participating in Clinical Trials

Discuss the benefits and risks with your physician if you're interested in participating in a clinical trial or cancer research in the Fort Worth area. Benefits include being actively involved in your healthcare, getting access to new treatments and medical care, and helping to further medical research. Risks may include unpleasant or serious side effects, treatments that are ineffective, and trials which take more time than standard treatment.

Clinical Trial Eligibility

Your eligibility for a clinical trial depends on several criteria, including your age and sex, your cancer type and stage of the cancer, previous treatments, and your overall medical history. View the list below of open clinical trials and cancer research opportunities in the Fort Worth area and talk to you doctor to determine which clinical trial is right for you.

Biliary Cancer

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: III

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 Study of Zanidatamab subjects with HER2+ Bilary Tract Cancer (BTC) View

Description: An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer (JZP598-302)

Indication: Biliary Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Study of Zanidatamab subjects with HER2+ Bilary Tract Cancer (BTC) View

Description: An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer (JZP598-302)

Indication: Biliary Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Study of Zanidatamab subjects with HER2+ Bilary Tract Cancer (BTC) View

Description: An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer (JZP598-302)

Indication: Biliary Cancer

Location: Texas Oncology-Grapevine

Phase: III

Bladder Cancer

Title: QUILT-2.005: A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination with ALT-803 (N-803) in Patients with Non-Muscle Invasive Bladder Cancer

Indication: Bladder Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: QUILT-2.005: A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination with ALT-803 (N-803) in Patients with Non-Muscle Invasive Bladder Cancer

Indication: Bladder Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: II

Title: Sacral Neuromodulation for Male OverActive Bladder (MOAB) Study

Indication: Bladder Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: IV

Title: Sacral Neuromodulation for Male OverActive Bladder (MOAB) Study

Indication: Bladder Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: IV

Breast Cancer

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Arlington Cancer Center North

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: Ph1 INCB123667 Mono & Combo w/ Anticancer Therapies in Solid Tumors View

Description: A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy and in Combination With Anticancer Therapies in Participants With Selected Advanced Solid Tumors (INCB 123667-101)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast View

Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)

Indication: Breast Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast View

Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)

Indication: Breast Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: III

Title: Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast View

Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast View

Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast View

Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast View

Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph1b/3 Study of Capivasertib + CDK4/6 Receptor 2-Neg mBreast (CAPItello-292) View

Description: A Phase Ib/III Open-label Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced Unresectable or Metastatic Breast Cancer (CAPItello-292) (D361DC00001)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph1 Study of TNBC residual disease detection and therapy monitoring in patients with Breast Cancer View

Description: Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I) (01-PS-001)

Indication: Breast Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I

Title: Ph1 Study of TNBC residual disease detection and therapy monitoring in patients with Breast Cancer View

Description: Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I) (01-PS-001)

Indication: Breast Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: I

Title: Ph1 Study of TNBC residual disease detection and therapy monitoring in patients with Breast Cancer View

Description: Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I) (01-PS-001)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: I

Title: Ph1 Study of TNBC residual disease detection and therapy monitoring in patients with Breast Cancer View

Description: Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I) (01-PS-001)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: I

Title: Ph1 Study of TNBC residual disease detection and therapy monitoring in patients with Breast Cancer View

Description: Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I) (01-PS-001)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 Study of TNBC residual disease detection and therapy monitoring in patients with Breast Cancer View

Description: Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I) (01-PS-001)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: I

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: II

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: III

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: II

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: III

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph2 study to evaluate pembro in epidermal growth factor receptor-2 negative breast cancer View

Description: An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03) (MK-1022-010)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Cervical Cancer

Title: Ph3 robotic Hysterectomy ROCC View

Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)

Indication: Cervical Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 robotic Hysterectomy ROCC View

Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)

Indication: Cervical Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors View

Description: A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01)

Indication: Cervical Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: GOG-3101: Ph3 study for MK2870 patients with recurrent or met cervical cancer View

Description: A Phase 3 Randomized Active-controlled Open-label Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physicians Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20) (MK2870-020-00)

Indication: Cervical Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: GOG-3101: Ph3 study for MK2870 patients with recurrent or met cervical cancer View

Description: A Phase 3 Randomized Active-controlled Open-label Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physicians Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20) (MK2870-020-00)

Indication: Cervical Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Colon Cancer

Title: Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway (0902-001)

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph3 study of FOLFIRI in participants with metastatic colorectal cancer View

Description: A Randomized Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BFAF Wild-Type Recurrent Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (61186372COR3002)

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Endometrial Cancer

Title: Ph2 ZN-c3 Uterine Carcinoma View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma (ZN-c3-004 GOG 3065)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph1b/2 ACR-368 w/ Gem Ovar Endom & Bladder View

Description: A PHASE 1B/2 BASKET STUDY OF ACR-368 AS MONOTHERAPY AND IN COMBINATION WITH GEMCITABINE IN ADULT SUBJECTS WITH PLATINUM-RESISTANT OVARIAN CARCINOMA ENDOMETRIAL ADENOCARCINOMA AND UROTHELIAL CARCINOMA BASED ON ACRIVON ONCOSIGNATURE STATUS (ACR-368-201/GOG-3082)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: Ph1 INCB123667 Mono & Combo w/ Anticancer Therapies in Solid Tumors View

Description: A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy and in Combination With Anticancer Therapies in Participants With Selected Advanced Solid Tumors (INCB 123667-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph3 Selin P53 Endo Carcinoma View

Description: A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)

Indication: Endometrial Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Selin P53 Endo Carcinoma View

Description: A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph3 study of GOG-3104 with endometrial cancer View

Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy (GS-US-682-6769)

Indication: Endometrial Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph3 study of GOG-3104 with endometrial cancer View

Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy (GS-US-682-6769)

Indication: Endometrial Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: III

Title: Ph3 study of GOG-3104 with endometrial cancer View

Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy (GS-US-682-6769)

Indication: Endometrial Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 study of GOG-3104 with endometrial cancer View

Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy (GS-US-682-6769)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Esophageal Cancer

Title: Ph1 INCB123667 Mono & Combo w/ Anticancer Therapies in Solid Tumors View

Description: A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy and in Combination With Anticancer Therapies in Participants With Selected Advanced Solid Tumors (INCB 123667-101)

Indication: Esophageal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Fallopian Tube Cancer

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Gastric Cancer

Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: II

Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph1 INCB123667 Mono & Combo w/ Anticancer Therapies in Solid Tumors View

Description: A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy and in Combination With Anticancer Therapies in Participants With Selected Advanced Solid Tumors (INCB 123667-101)

Indication: Gastric Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Gastric Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Gastric Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Head and Neck Cancer

Title: A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Indication: Head and Neck Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Head and Neck Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Leukemia

Title: Ibrutinib Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (JNJ-54179060) View

Description: Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (54179060CLL2032)

Indication: Leukemia

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Liver Cancer

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Liver Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Lung Cancer

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II/III

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: II/III

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II/III

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II/III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway (0902-001)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: II

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph2 Randomized dose-optimization study of alisertib in patients with SCLC (PB-8237) View

Description: A PHASE 2 STUDY OF ALISERTIB IN PATIENTS WITH EXTENSIVE SMALL CELL LUNG CANCER (PUMA-ALI-4201)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph3 Tarlatamab in combo with Durvalumab ES-SCLC View

Description: A Phase 3 Open-label Multicenter Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small-Cell Lung Cancer Following Platinum Etoposide and Durvalumab (DeLLphi-305) (20200041)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II/III

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: II/III

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II/III

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II/III

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II/III

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II/III

Title: Ph3 study of Dato-DXd with stage I adenocarcinoma NSCLC (TROPION-Lung12) View

Description: A Phase III Randomised Open-label Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care Following Complete Tumour Resection in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features (TROPION-Lung12) (D926TC00001)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph3 study of Dato-DXd with stage I adenocarcinoma NSCLC (TROPION-Lung12) View

Description: A Phase III Randomised Open-label Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care Following Complete Tumour Resection in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features (TROPION-Lung12) (D926TC00001)

Indication: Lung Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: III

Title: Ph3 study of Dato-DXd with stage I adenocarcinoma NSCLC (TROPION-Lung12) View

Description: A Phase III Randomised Open-label Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care Following Complete Tumour Resection in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features (TROPION-Lung12) (D926TC00001)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: Ph3 study of Dato-DXd with stage I adenocarcinoma NSCLC (TROPION-Lung12) View

Description: A Phase III Randomised Open-label Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care Following Complete Tumour Resection in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features (TROPION-Lung12) (D926TC00001)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 study of Dato-DXd with stage I adenocarcinoma NSCLC (TROPION-Lung12) View

Description: A Phase III Randomised Open-label Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care Following Complete Tumour Resection in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features (TROPION-Lung12) (D926TC00001)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 study of Dato-DXd with stage I adenocarcinoma NSCLC (TROPION-Lung12) View

Description: A Phase III Randomised Open-label Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care Following Complete Tumour Resection in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features (TROPION-Lung12) (D926TC00001)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph3 of Ivonescimab vs pembro for patients with NSCLC (HARMONi-7) View

Description: A Randomized Double-blinded Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression(HARMONi-7)(SMT-112-3007)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 of Ivonescimab vs pembro for patients with NSCLC (HARMONi-7) View

Description: A Randomized Double-blinded Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression(HARMONi-7)(SMT-112-3007)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: III

Lymphomas

Title: Ph3 Glofitamab (RO7082859) in combo with POLA-R-CHP B-Cell Lymphoma View

Description: A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING THE EFFICACY AND SAFETY OF GLOFITAMAB (RO7082859) IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB CYCLOPHOSPHAMIDE DOXORUBICIN AND PREDNISONE (POLA-R-CHP) VERSUS POLA R CHP IN PREVIOUSLY UNTREATED PATIENTS WITH LARGE B-CELL LYMPHOMA (GO44145)

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Study of (EPCORE FL-2) in previously untreated follicular lymphoma View

Description: A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2) (M22-003)

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: II

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Arlington South

Phase: II

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Grapevine

Phase: II

Melanoma

Title: Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma View

Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)

Indication: Melanoma

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma View

Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)

Indication: Melanoma

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma View

Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)

Indication: Melanoma

Location: Texas Oncology-Grapevine

Phase: III

Myelofibrosis

Title: A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms (LIMBER-103)

Indication: Myelofibrosis

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Ovarian Cancer

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph1b/2 ACR-368 w/ Gem Ovar Endom & Bladder View

Description: A PHASE 1B/2 BASKET STUDY OF ACR-368 AS MONOTHERAPY AND IN COMBINATION WITH GEMCITABINE IN ADULT SUBJECTS WITH PLATINUM-RESISTANT OVARIAN CARCINOMA ENDOMETRIAL ADENOCARCINOMA AND UROTHELIAL CARCINOMA BASED ON ACRIVON ONCOSIGNATURE STATUS (ACR-368-201/GOG-3082)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph1 NXP800 Ovarian Cancer View

Description: A Phase 1 Clinical Study of NXP800 in Subjects with Advanced Cancers and Expansion in Subjects with Ovarian Cancer (NXP800-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: III

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph2 stud of TORL-1-23 in women with epithelial and fallopian tube cancers (CLDN6) View

Description: A Phase 2 Study Evaluating The Efficacy And Safety Of TORL-1-23 In Women With Advanced Platinum Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal And Fallopian Tube Cancers) Expressing Claudin 6 (TORL123-002)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: Ph2 stud of TORL-1-23 in women with epithelial and fallopian tube cancers (CLDN6) View

Description: A Phase 2 Study Evaluating The Efficacy And Safety Of TORL-1-23 In Women With Advanced Platinum Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal And Fallopian Tube Cancers) Expressing Claudin 6 (TORL123-002)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: II

Title: Ph2 stud of TORL-1-23 in women with epithelial and fallopian tube cancers (CLDN6) View

Description: A Phase 2 Study Evaluating The Efficacy And Safety Of TORL-1-23 In Women With Advanced Platinum Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal And Fallopian Tube Cancers) Expressing Claudin 6 (TORL123-002)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2 stud of TORL-1-23 in women with epithelial and fallopian tube cancers (CLDN6) View

Description: A Phase 2 Study Evaluating The Efficacy And Safety Of TORL-1-23 In Women With Advanced Platinum Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal And Fallopian Tube Cancers) Expressing Claudin 6 (TORL123-002)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph3 study of Rina-S versus treatment of investigator choice with ovarian cancer View

Description: A Phase 3 Randomized Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigators Choice (IC) in Patients with Platinum Resistant Ovarian Cancer (GCT1184-02)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph3 study of Rina-S versus treatment of investigator choice with ovarian cancer View

Description: A Phase 3 Randomized Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigators Choice (IC) in Patients with Platinum Resistant Ovarian Cancer (GCT1184-02)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: III

Title: Ph3 study of Rina-S versus treatment of investigator choice with ovarian cancer View

Description: A Phase 3 Randomized Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigators Choice (IC) in Patients with Platinum Resistant Ovarian Cancer (GCT1184-02)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 study of Rina-S versus treatment of investigator choice with ovarian cancer View

Description: A Phase 3 Randomized Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigators Choice (IC) in Patients with Platinum Resistant Ovarian Cancer (GCT1184-02)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Pancreatic Cancer

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Pancreatic Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph3 study of RMC-6236 in patients with met pancreatic ductal adenocarcinoma (PDAC) View

Description: A Phase 3 Multicenter Open-label Randomized Study of RMC-6236 versus Investigator's Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RMC-6236-302)

Indication: Pancreatic Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 study of RMC-6236 in patients with met pancreatic ductal adenocarcinoma (PDAC) View

Description: A Phase 3 Multicenter Open-label Randomized Study of RMC-6236 versus Investigator's Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RMC-6236-302)

Indication: Pancreatic Cancer

Location: Texas Oncology-Grapevine

Phase: III

Peritoneal Cancer

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Peritoneal Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Peritoneal Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Peritoneal Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Prostate Cancer

Title: Ph3 study of MK-5684 versus alternative NHA in mCRPC View

Description: A Phase 3 Randomized Open-label Study of Opevesostat versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) (OMAHA-004) (MK-5684-004)

Indication: Prostate Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 study of MK-5684 versus alternative NHA in mCRPC View

Description: A Phase 3 Randomized Open-label Study of Opevesostat versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) (OMAHA-004) (MK-5684-004)

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Rectal Cancer

Title: Ph3 study of FOLFIRI in participants with metastatic colorectal cancer View

Description: A Randomized Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BFAF Wild-Type Recurrent Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (61186372COR3002)

Indication: Rectal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Solid Tumors

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors GCT1184-01 (PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors GCT1184-01 (PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway (0902-001)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Arlington Cancer Center North

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Arlington South

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: IV

Title: Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors View

Description: A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: I/II

Urothelial Cancer

Title: Ph1b/2 ACR-368 w/ Gem Ovar Endom & Bladder View

Description: A PHASE 1B/2 BASKET STUDY OF ACR-368 AS MONOTHERAPY AND IN COMBINATION WITH GEMCITABINE IN ADULT SUBJECTS WITH PLATINUM-RESISTANT OVARIAN CARCINOMA ENDOMETRIAL ADENOCARCINOMA AND UROTHELIAL CARCINOMA BASED ON ACRIVON ONCOSIGNATURE STATUS (ACR-368-201/GOG-3082)

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors View

Description: A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01)

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Uterine Cancer

Title: Ph2 ZN-c3 Uterine Carcinoma View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma (ZN-c3-004 GOG 3065)

Indication: Uterine Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph1 INCB123667 Mono & Combo w/ Anticancer Therapies in Solid Tumors View

Description: A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy and in Combination With Anticancer Therapies in Participants With Selected Advanced Solid Tumors (INCB 123667-101)

Indication: Uterine Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Texas Oncology-Arlington Cancer Center North

Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: QUILT-2.005: A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination with ALT-803 (N-803) in Patients with Non-Muscle Invasive Bladder Cancer

Indication: Bladder Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: Sacral Neuromodulation for Male OverActive Bladder (MOAB) Study

Indication: Bladder Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: IV

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Arlington Cancer Center North

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast View

Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)

Indication: Breast Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph1 Study of TNBC residual disease detection and therapy monitoring in patients with Breast Cancer View

Description: Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I) (01-PS-001)

Indication: Breast Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: Ph3 study of GOG-3104 with endometrial cancer View

Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy (GS-US-682-6769)

Indication: Endometrial Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II/III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II/III

Title: Ph3 study of Dato-DXd with stage I adenocarcinoma NSCLC (TROPION-Lung12) View

Description: A Phase III Randomised Open-label Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care Following Complete Tumour Resection in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features (TROPION-Lung12) (D926TC00001)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph2 stud of TORL-1-23 in women with epithelial and fallopian tube cancers (CLDN6) View

Description: A Phase 2 Study Evaluating The Efficacy And Safety Of TORL-1-23 In Women With Advanced Platinum Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal And Fallopian Tube Cancers) Expressing Claudin 6 (TORL123-002)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: Ph3 study of Rina-S versus treatment of investigator choice with ovarian cancer View

Description: A Phase 3 Randomized Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigators Choice (IC) in Patients with Platinum Resistant Ovarian Cancer (GCT1184-02)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Peritoneal Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Arlington Cancer Center North

Phase: IV

Texas Oncology-Arlington North Radiation Oncology

Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: II

Title: QUILT-2.005: A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination with ALT-803 (N-803) in Patients with Non-Muscle Invasive Bladder Cancer

Indication: Bladder Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: II

Title: Sacral Neuromodulation for Male OverActive Bladder (MOAB) Study

Indication: Bladder Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: IV

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: II

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: III

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: I/II

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: III

Title: Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast View

Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)

Indication: Breast Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: III

Title: Ph1 Study of TNBC residual disease detection and therapy monitoring in patients with Breast Cancer View

Description: Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I) (01-PS-001)

Indication: Breast Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: I

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: II

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: III

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: II

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: I/II

Title: Ph3 study of GOG-3104 with endometrial cancer View

Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy (GS-US-682-6769)

Indication: Endometrial Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: III

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: II

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: III

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: II/III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: I/II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: II

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: II

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: II/III

Title: Ph3 study of Dato-DXd with stage I adenocarcinoma NSCLC (TROPION-Lung12) View

Description: A Phase III Randomised Open-label Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care Following Complete Tumour Resection in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features (TROPION-Lung12) (D926TC00001)

Indication: Lung Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: III

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: II

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: I/II

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: III

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: III

Title: Ph2 stud of TORL-1-23 in women with epithelial and fallopian tube cancers (CLDN6) View

Description: A Phase 2 Study Evaluating The Efficacy And Safety Of TORL-1-23 In Women With Advanced Platinum Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal And Fallopian Tube Cancers) Expressing Claudin 6 (TORL123-002)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: II

Title: Ph3 study of Rina-S versus treatment of investigator choice with ovarian cancer View

Description: A Phase 3 Randomized Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigators Choice (IC) in Patients with Platinum Resistant Ovarian Cancer (GCT1184-02)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: III

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: II

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Peritoneal Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: I/II

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: IV

Texas Oncology-Arlington South

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast View

Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: Ph1 Study of TNBC residual disease detection and therapy monitoring in patients with Breast Cancer View

Description: Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I) (01-PS-001)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: I

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II/III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II/III

Title: Ph3 study of Dato-DXd with stage I adenocarcinoma NSCLC (TROPION-Lung12) View

Description: A Phase III Randomised Open-label Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care Following Complete Tumour Resection in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features (TROPION-Lung12) (D926TC00001)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Arlington South

Phase: IV

Texas Oncology-Bedford

Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Study of Zanidatamab subjects with HER2+ Bilary Tract Cancer (BTC) View

Description: An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer (JZP598-302)

Indication: Biliary Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast View

Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph1 Study of TNBC residual disease detection and therapy monitoring in patients with Breast Cancer View

Description: Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I) (01-PS-001)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: I

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 robotic Hysterectomy ROCC View

Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)

Indication: Cervical Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: GOG-3101: Ph3 study for MK2870 patients with recurrent or met cervical cancer View

Description: A Phase 3 Randomized Active-controlled Open-label Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physicians Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20) (MK2870-020-00)

Indication: Cervical Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: Ph3 Selin P53 Endo Carcinoma View

Description: A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)

Indication: Endometrial Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 study of GOG-3104 with endometrial cancer View

Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy (GS-US-682-6769)

Indication: Endometrial Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II/III

Title: Ph3 study of Dato-DXd with stage I adenocarcinoma NSCLC (TROPION-Lung12) View

Description: A Phase III Randomised Open-label Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care Following Complete Tumour Resection in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features (TROPION-Lung12) (D926TC00001)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Bedford

Phase: II

Title: Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma View

Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)

Indication: Melanoma

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph2 stud of TORL-1-23 in women with epithelial and fallopian tube cancers (CLDN6) View

Description: A Phase 2 Study Evaluating The Efficacy And Safety Of TORL-1-23 In Women With Advanced Platinum Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal And Fallopian Tube Cancers) Expressing Claudin 6 (TORL123-002)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph3 study of Rina-S versus treatment of investigator choice with ovarian cancer View

Description: A Phase 3 Randomized Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigators Choice (IC) in Patients with Platinum Resistant Ovarian Cancer (GCT1184-02)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Peritoneal Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 study of MK-5684 versus alternative NHA in mCRPC View

Description: A Phase 3 Randomized Open-label Study of Opevesostat versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) (OMAHA-004) (MK-5684-004)

Indication: Prostate Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors GCT1184-01 (PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: IV

Texas Oncology-Fort Worth Cancer Center

Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Indication: Head and Neck Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms (LIMBER-103)

Indication: Myelofibrosis

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Study of Zanidatamab subjects with HER2+ Bilary Tract Cancer (BTC) View

Description: An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer (JZP598-302)

Indication: Biliary Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph1 INCB123667 Mono & Combo w/ Anticancer Therapies in Solid Tumors View

Description: A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy and in Combination With Anticancer Therapies in Participants With Selected Advanced Solid Tumors (INCB 123667-101)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast View

Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph1b/3 Study of Capivasertib + CDK4/6 Receptor 2-Neg mBreast (CAPItello-292) View

Description: A Phase Ib/III Open-label Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced Unresectable or Metastatic Breast Cancer (CAPItello-292) (D361DC00001)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph1 Study of TNBC residual disease detection and therapy monitoring in patients with Breast Cancer View

Description: Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I) (01-PS-001)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph2 study to evaluate pembro in epidermal growth factor receptor-2 negative breast cancer View

Description: An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03) (MK-1022-010)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph3 robotic Hysterectomy ROCC View

Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)

Indication: Cervical Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors View

Description: A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01)

Indication: Cervical Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: GOG-3101: Ph3 study for MK2870 patients with recurrent or met cervical cancer View

Description: A Phase 3 Randomized Active-controlled Open-label Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physicians Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20) (MK2870-020-00)

Indication: Cervical Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway (0902-001)

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph3 study of FOLFIRI in participants with metastatic colorectal cancer View

Description: A Randomized Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BFAF Wild-Type Recurrent Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (61186372COR3002)

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph2 ZN-c3 Uterine Carcinoma View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma (ZN-c3-004 GOG 3065)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph1b/2 ACR-368 w/ Gem Ovar Endom & Bladder View

Description: A PHASE 1B/2 BASKET STUDY OF ACR-368 AS MONOTHERAPY AND IN COMBINATION WITH GEMCITABINE IN ADULT SUBJECTS WITH PLATINUM-RESISTANT OVARIAN CARCINOMA ENDOMETRIAL ADENOCARCINOMA AND UROTHELIAL CARCINOMA BASED ON ACRIVON ONCOSIGNATURE STATUS (ACR-368-201/GOG-3082)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph1 INCB123667 Mono & Combo w/ Anticancer Therapies in Solid Tumors View

Description: A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy and in Combination With Anticancer Therapies in Participants With Selected Advanced Solid Tumors (INCB 123667-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph3 Selin P53 Endo Carcinoma View

Description: A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph3 study of GOG-3104 with endometrial cancer View

Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy (GS-US-682-6769)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph1 INCB123667 Mono & Combo w/ Anticancer Therapies in Solid Tumors View

Description: A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy and in Combination With Anticancer Therapies in Participants With Selected Advanced Solid Tumors (INCB 123667-101)

Indication: Esophageal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph1 INCB123667 Mono & Combo w/ Anticancer Therapies in Solid Tumors View

Description: A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy and in Combination With Anticancer Therapies in Participants With Selected Advanced Solid Tumors (INCB 123667-101)

Indication: Gastric Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Gastric Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Gastric Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Head and Neck Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ibrutinib Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (JNJ-54179060) View

Description: Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (54179060CLL2032)

Indication: Leukemia

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Liver Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway (0902-001)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 Randomized dose-optimization study of alisertib in patients with SCLC (PB-8237) View

Description: A PHASE 2 STUDY OF ALISERTIB IN PATIENTS WITH EXTENSIVE SMALL CELL LUNG CANCER (PUMA-ALI-4201)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph3 Tarlatamab in combo with Durvalumab ES-SCLC View

Description: A Phase 3 Open-label Multicenter Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small-Cell Lung Cancer Following Platinum Etoposide and Durvalumab (DeLLphi-305) (20200041)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II/III

Title: Ph3 study of Dato-DXd with stage I adenocarcinoma NSCLC (TROPION-Lung12) View

Description: A Phase III Randomised Open-label Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care Following Complete Tumour Resection in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features (TROPION-Lung12) (D926TC00001)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph3 of Ivonescimab vs pembro for patients with NSCLC (HARMONi-7) View

Description: A Randomized Double-blinded Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression(HARMONi-7)(SMT-112-3007)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Glofitamab (RO7082859) in combo with POLA-R-CHP B-Cell Lymphoma View

Description: A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING THE EFFICACY AND SAFETY OF GLOFITAMAB (RO7082859) IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB CYCLOPHOSPHAMIDE DOXORUBICIN AND PREDNISONE (POLA-R-CHP) VERSUS POLA R CHP IN PREVIOUSLY UNTREATED PATIENTS WITH LARGE B-CELL LYMPHOMA (GO44145)

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Study of (EPCORE FL-2) in previously untreated follicular lymphoma View

Description: A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2) (M22-003)

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma View

Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)

Indication: Melanoma

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph1b/2 ACR-368 w/ Gem Ovar Endom & Bladder View

Description: A PHASE 1B/2 BASKET STUDY OF ACR-368 AS MONOTHERAPY AND IN COMBINATION WITH GEMCITABINE IN ADULT SUBJECTS WITH PLATINUM-RESISTANT OVARIAN CARCINOMA ENDOMETRIAL ADENOCARCINOMA AND UROTHELIAL CARCINOMA BASED ON ACRIVON ONCOSIGNATURE STATUS (ACR-368-201/GOG-3082)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph1 NXP800 Ovarian Cancer View

Description: A Phase 1 Clinical Study of NXP800 in Subjects with Advanced Cancers and Expansion in Subjects with Ovarian Cancer (NXP800-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph2 stud of TORL-1-23 in women with epithelial and fallopian tube cancers (CLDN6) View

Description: A Phase 2 Study Evaluating The Efficacy And Safety Of TORL-1-23 In Women With Advanced Platinum Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal And Fallopian Tube Cancers) Expressing Claudin 6 (TORL123-002)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph3 study of Rina-S versus treatment of investigator choice with ovarian cancer View

Description: A Phase 3 Randomized Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigators Choice (IC) in Patients with Platinum Resistant Ovarian Cancer (GCT1184-02)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Pancreatic Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph3 study of RMC-6236 in patients with met pancreatic ductal adenocarcinoma (PDAC) View

Description: A Phase 3 Multicenter Open-label Randomized Study of RMC-6236 versus Investigator's Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RMC-6236-302)

Indication: Pancreatic Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 study of MK-5684 versus alternative NHA in mCRPC View

Description: A Phase 3 Randomized Open-label Study of Opevesostat versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) (OMAHA-004) (MK-5684-004)

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 study of FOLFIRI in participants with metastatic colorectal cancer View

Description: A Randomized Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BFAF Wild-Type Recurrent Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (61186372COR3002)

Indication: Rectal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors GCT1184-01 (PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway (0902-001)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: IV

Title: Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors View

Description: A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph1b/2 ACR-368 w/ Gem Ovar Endom & Bladder View

Description: A PHASE 1B/2 BASKET STUDY OF ACR-368 AS MONOTHERAPY AND IN COMBINATION WITH GEMCITABINE IN ADULT SUBJECTS WITH PLATINUM-RESISTANT OVARIAN CARCINOMA ENDOMETRIAL ADENOCARCINOMA AND UROTHELIAL CARCINOMA BASED ON ACRIVON ONCOSIGNATURE STATUS (ACR-368-201/GOG-3082)

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors View

Description: A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01)

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph2 ZN-c3 Uterine Carcinoma View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma (ZN-c3-004 GOG 3065)

Indication: Uterine Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph1 INCB123667 Mono & Combo w/ Anticancer Therapies in Solid Tumors View

Description: A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy and in Combination With Anticancer Therapies in Participants With Selected Advanced Solid Tumors (INCB 123667-101)

Indication: Uterine Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Texas Oncology-Grapevine

Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 Study of Zanidatamab subjects with HER2+ Bilary Tract Cancer (BTC) View

Description: An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer (JZP598-302)

Indication: Biliary Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast View

Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph1 Study of TNBC residual disease detection and therapy monitoring in patients with Breast Cancer View

Description: Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I) (01-PS-001)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: I

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II/III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II/III

Title: Ph3 study of Dato-DXd with stage I adenocarcinoma NSCLC (TROPION-Lung12) View

Description: A Phase III Randomised Open-label Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care Following Complete Tumour Resection in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features (TROPION-Lung12) (D926TC00001)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph3 of Ivonescimab vs pembro for patients with NSCLC (HARMONi-7) View

Description: A Randomized Double-blinded Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression(HARMONi-7)(SMT-112-3007)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma View

Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)

Indication: Melanoma

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: Ph3 study of RMC-6236 in patients with met pancreatic ductal adenocarcinoma (PDAC) View

Description: A Phase 3 Multicenter Open-label Randomized Study of RMC-6236 versus Investigator's Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RMC-6236-302)

Indication: Pancreatic Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: IV

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: I/II

No Phase

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Arlington Cancer Center North

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase I

Title: A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms (LIMBER-103)

Indication: Myelofibrosis

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 INCB123667 Mono & Combo w/ Anticancer Therapies in Solid Tumors View

Description: A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy and in Combination With Anticancer Therapies in Participants With Selected Advanced Solid Tumors (INCB 123667-101)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 Study of TNBC residual disease detection and therapy monitoring in patients with Breast Cancer View

Description: Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I) (01-PS-001)

Indication: Breast Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I

Title: Ph1 Study of TNBC residual disease detection and therapy monitoring in patients with Breast Cancer View

Description: Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I) (01-PS-001)

Indication: Breast Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: I

Title: Ph1 Study of TNBC residual disease detection and therapy monitoring in patients with Breast Cancer View

Description: Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I) (01-PS-001)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: I

Title: Ph1 Study of TNBC residual disease detection and therapy monitoring in patients with Breast Cancer View

Description: Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I) (01-PS-001)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: I

Title: Ph1 Study of TNBC residual disease detection and therapy monitoring in patients with Breast Cancer View

Description: Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I) (01-PS-001)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 Study of TNBC residual disease detection and therapy monitoring in patients with Breast Cancer View

Description: Breast Cancer-Minimal/Molecular Residual Disease Detection and Therapy Monitoring in Patients with Early Stage TNBC-Phase I (B-STRONGER-I) (01-PS-001)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: I

Title: Ph1 INCB123667 Mono & Combo w/ Anticancer Therapies in Solid Tumors View

Description: A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy and in Combination With Anticancer Therapies in Participants With Selected Advanced Solid Tumors (INCB 123667-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 INCB123667 Mono & Combo w/ Anticancer Therapies in Solid Tumors View

Description: A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy and in Combination With Anticancer Therapies in Participants With Selected Advanced Solid Tumors (INCB 123667-101)

Indication: Esophageal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Esophageal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 INCB123667 Mono & Combo w/ Anticancer Therapies in Solid Tumors View

Description: A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy and in Combination With Anticancer Therapies in Participants With Selected Advanced Solid Tumors (INCB 123667-101)

Indication: Gastric Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Gastric Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 NXP800 Ovarian Cancer View

Description: A Phase 1 Clinical Study of NXP800 in Subjects with Advanced Cancers and Expansion in Subjects with Ovarian Cancer (NXP800-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 FIH Study of TORL-2-307-ADC in Patients with Pancreatic Gastric or GEJ View

Description: A PHASE 1 FIRST IN HUMAN DOSE-ESCALATION STUDY OF TORL-2-307-ADC IN PARTICIPANTS WITH ADVANCED CANCER (TORL2307ADC-001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1 INCB123667 Mono & Combo w/ Anticancer Therapies in Solid Tumors View

Description: A Phase 1 Open-Label Multicenter Study of INCB123667 as Monotherapy and in Combination With Anticancer Therapies in Participants With Selected Advanced Solid Tumors (INCB 123667-101)

Indication: Uterine Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Phase I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors View

Description: A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01)

Indication: Cervical Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway (0902-001)

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph1b/2 ACR-368 w/ Gem Ovar Endom & Bladder View

Description: A PHASE 1B/2 BASKET STUDY OF ACR-368 AS MONOTHERAPY AND IN COMBINATION WITH GEMCITABINE IN ADULT SUBJECTS WITH PLATINUM-RESISTANT OVARIAN CARCINOMA ENDOMETRIAL ADENOCARCINOMA AND UROTHELIAL CARCINOMA BASED ON ACRIVON ONCOSIGNATURE STATUS (ACR-368-201/GOG-3082)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Endometrial Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway (0902-001)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph1b/2 ACR-368 w/ Gem Ovar Endom & Bladder View

Description: A PHASE 1B/2 BASKET STUDY OF ACR-368 AS MONOTHERAPY AND IN COMBINATION WITH GEMCITABINE IN ADULT SUBJECTS WITH PLATINUM-RESISTANT OVARIAN CARCINOMA ENDOMETRIAL ADENOCARCINOMA AND UROTHELIAL CARCINOMA BASED ON ACRIVON ONCOSIGNATURE STATUS (ACR-368-201/GOG-3082)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors GCT1184-01 (PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: I/II

Title: Ph1/2 FIH RO1184 FOLR1 Select Solid Tumors View

Description: Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors GCT1184-01 (PRO1184-001)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph1/2 FIH SOS1 MRTX0902 Solid Tumors KRAS-MAPK Pathway View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of the SOS1 Inhibitor MRTX0902 in Patients with Advanced Solid Tumors Harboring Mutations in the KRAS-MAPK Pathway (0902-001)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors View

Description: A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: I/II

Title: Ph1b/2 ACR-368 w/ Gem Ovar Endom & Bladder View

Description: A PHASE 1B/2 BASKET STUDY OF ACR-368 AS MONOTHERAPY AND IN COMBINATION WITH GEMCITABINE IN ADULT SUBJECTS WITH PLATINUM-RESISTANT OVARIAN CARCINOMA ENDOMETRIAL ADENOCARCINOMA AND UROTHELIAL CARCINOMA BASED ON ACRIVON ONCOSIGNATURE STATUS (ACR-368-201/GOG-3082)

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph1/2 Study to Investigate PKs of CRB-701 Nectin-4 with Solid Tumors View

Description: A Phase 1/2 Study to Investigate the Safety Pharmacokinetics and Efficacy of CRB-701 an Antibody Drug Conjugate Targeting Nectin-4 in Patients with Advanced Solid Tumors (CRB-701-01)

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Phase II

Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: II

Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Indication: Gastric Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: QUILT-2.005: A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination with ALT-803 (N-803) in Patients with Non-Muscle Invasive Bladder Cancer

Indication: Bladder Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: QUILT-2.005: A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination with ALT-803 (N-803) in Patients with Non-Muscle Invasive Bladder Cancer

Indication: Bladder Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: II

Title: A Phase 2, Randomized, Multicenter, Open-label, Study of FID-007 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Indication: Head and Neck Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: II

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 Study of Alisertib in combo with endocrine therapy in HR+ HER2 met Breast cancer View

Description: A Phase 2 study of Alisertib in combination with endocrine therapy in patients with HR+ HER2-negative Recurrent or metastatic breast cancer (PUMA-ALI-1201)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: II

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 clinical trial of BNT327 in combo with treatment in breast cancer View

Description: A Phase II multi-site randomized open-label clinical trial to evaluate the safety efficacy and pharmacokinetics of BNT327 at two dose levels in combination with chemotherapeutic agents as first- and second-line treatment in triple-negative breast cancer (BNT327-02)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph2 study to evaluate pembro in epidermal growth factor receptor-2 negative breast cancer View

Description: An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03) (MK-1022-010)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 ZN-c3 Uterine Carcinoma View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma (ZN-c3-004 GOG 3065)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Gastric Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Head and Neck Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ibrutinib Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (JNJ-54179060) View

Description: Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (54179060CLL2032)

Indication: Leukemia

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Liver Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 Adagrasib NSCLC KRAS G12C Mutation (KRYSTAL-17) View

Description: A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: II

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 Study of EIK1001 in combo with pembro in patients with stage 4 NSCLC View

Description: A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer (EIK1001-005)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph2 Randomized dose-optimization study of alisertib in patients with SCLC (PB-8237) View

Description: A PHASE 2 STUDY OF ALISERTIB IN PATIENTS WITH EXTENSIVE SMALL CELL LUNG CANCER (PUMA-ALI-4201)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 study of AMG 193 in subjects with MTAP deleted in previously treated NSCLC View

Description: A Phase 2 Study Evaluating the Efficacy Safety Tolerability and Pharmacokinetics of AMG 193 in Subjects with MethylthioadenosinePhosphorylase (MTAP)-deleted Previously Treated Advanced Non- Small Cell Lung Cancer (NSCLC) (20230153)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 Multi-cohort study of subcutaneous Amivantamab in NSCLC (COPERNICUS) View

Description: A Phase 2b Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS) (61186372NSC2012)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: II

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Arlington South

Phase: II

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 study of ALLO-501A in disease for large b-cell lymphoma (ALPHA3) View

Description: A RANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF CEMACABTAGENE ANSEGEDLEUCEL IN PARTICIPANTS WITH MINIMAL RESIDUAL DISEASE AFTER RESPONSE TO FIRST LINE THERAPY FORLARGE B-CELL LYMPHOMA (ALPHA3) [ALLO-501A-202]

Indication: Lymphomas

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Ovarian Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph2 stud of TORL-1-23 in women with epithelial and fallopian tube cancers (CLDN6) View

Description: A Phase 2 Study Evaluating The Efficacy And Safety Of TORL-1-23 In Women With Advanced Platinum Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal And Fallopian Tube Cancers) Expressing Claudin 6 (TORL123-002)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: Ph2 stud of TORL-1-23 in women with epithelial and fallopian tube cancers (CLDN6) View

Description: A Phase 2 Study Evaluating The Efficacy And Safety Of TORL-1-23 In Women With Advanced Platinum Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal And Fallopian Tube Cancers) Expressing Claudin 6 (TORL123-002)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: II

Title: Ph2 stud of TORL-1-23 in women with epithelial and fallopian tube cancers (CLDN6) View

Description: A Phase 2 Study Evaluating The Efficacy And Safety Of TORL-1-23 In Women With Advanced Platinum Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal And Fallopian Tube Cancers) Expressing Claudin 6 (TORL123-002)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2 stud of TORL-1-23 in women with epithelial and fallopian tube cancers (CLDN6) View

Description: A Phase 2 Study Evaluating The Efficacy And Safety Of TORL-1-23 In Women With Advanced Platinum Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal And Fallopian Tube Cancers) Expressing Claudin 6 (TORL123-002)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 Pan-Tumor Study of Ifnatamab Deruxtecan in Pts with Met Solid Tumors View

Description: A Phase 1b/2 Pan-Tumor Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (Ideate-Pantumor02) (DS7300-203)

Indication: Pancreatic Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066)

Indication: Peritoneal Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph2 ZN-c3 Uterine Carcinoma View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma (ZN-c3-004 GOG 3065)

Indication: Uterine Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Phase II/III

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II/III

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: II/III

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II/III

Title: Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II/III

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II/III

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: II/III

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II/III

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II/III

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II/III

Title: Ph2/3 Study of livmoniplimab in combo with budigalimab in untreated metastatic NSCLC (LIVIGNO-4) View

Description: A Randomized Phase 2/3 Study to Evaluate the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) - LIVIGNO-4 (M23-721)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II/III

Phase III

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: III

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 Oral Tinengotinib vs FGFR altered Cholangiocarcinoma (FIRST-308) View

Description: A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) (TT420C2308)

Indication: Biliary Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 Study of Zanidatamab subjects with HER2+ Bilary Tract Cancer (BTC) View

Description: An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer (JZP598-302)

Indication: Biliary Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Study of Zanidatamab subjects with HER2+ Bilary Tract Cancer (BTC) View

Description: An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer (JZP598-302)

Indication: Biliary Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Study of Zanidatamab subjects with HER2+ Bilary Tract Cancer (BTC) View

Description: An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer (JZP598-302)

Indication: Biliary Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: III

Title: Ph3 HER2/neu BC (FLAMINGO-01) View

Description: A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Deruxtecan with Durvalumab vs Pembrolizumab 3neg BC (Tropion Breast 04) View

Description: A Phase III Open-Label Randomized Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) View

Description: CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast View

Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)

Indication: Breast Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast View

Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)

Indication: Breast Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: III

Title: Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast View

Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast View

Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast View

Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Giredestrant CDK4/6 ER+ HER2- Advanced Breast View

Description: A PHASE III RANDOMIZED OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT BOTH COMBINED WITH A CDK4/6 INHIBITOR IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY (CO44657)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph1b/3 Study of Capivasertib + CDK4/6 Receptor 2-Neg mBreast (CAPItello-292) View

Description: A Phase Ib/III Open-label Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced Unresectable or Metastatic Breast Cancer (CAPItello-292) (D361DC00001)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Study of DB1303 in HER2-low with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02) View

Description: A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: III

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: ACCELERO: Ph3 study of HER2-positive controlled by physicians with metastatic breast cancer View

Description: A Phase 3 randomized open-label multicenter controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician's choice chemotherapy compared to trastuzumab in combination with physician's choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on or are intolerant to previous trastuzumab deruxtecan treatment (JZP598-303)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: III

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 study of standard endocrine therapy with breast cancer View

Description: Elacestrant versus Standard Endocrine Therapy in Women and Men with Node -positive Estrogen Receptor-positive HER2-negative Early Breast Cancer with High Risk of Recurrence - A Global Multicenter Randomized Open-label Phase 3 Study (ELEGANT)(STML-ELA-0422)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 robotic Hysterectomy ROCC View

Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)

Indication: Cervical Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 robotic Hysterectomy ROCC View

Description: (GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial)

Indication: Cervical Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: GOG-3101: Ph3 study for MK2870 patients with recurrent or met cervical cancer View

Description: A Phase 3 Randomized Active-controlled Open-label Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physicians Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20) (MK2870-020-00)

Indication: Cervical Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: GOG-3101: Ph3 study for MK2870 patients with recurrent or met cervical cancer View

Description: A Phase 3 Randomized Active-controlled Open-label Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physicians Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20) (MK2870-020-00)

Indication: Cervical Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 study of FOLFIRI in participants with metastatic colorectal cancer View

Description: A Randomized Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BFAF Wild-Type Recurrent Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (61186372COR3002)

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Selin P53 Endo Carcinoma View

Description: A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)

Indication: Endometrial Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Selin P53 Endo Carcinoma View

Description: A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 study of GOG-3104 with endometrial cancer View

Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy (GS-US-682-6769)

Indication: Endometrial Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph3 study of GOG-3104 with endometrial cancer View

Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy (GS-US-682-6769)

Indication: Endometrial Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: III

Title: Ph3 study of GOG-3104 with endometrial cancer View

Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy (GS-US-682-6769)

Indication: Endometrial Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 study of GOG-3104 with endometrial cancer View

Description: A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy (GS-US-682-6769)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 study to evaluate to treat patients with HNSCC View

Description: A phase 3 open-label randomized controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator's choice monotherapy treatment in previously treated patients with incurable metastatic/recurrent head and neck squamous cell carcinoma (MCLA-158-CL02)

Indication: Head and Neck Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 study of pembro in HNSCC in the disease without curative therapy available View

Description: A phase III randomized open label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs. pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma (MCLA-158-CL03)

Indication: Head and Neck Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer View

Description: Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Tarlatamab in combo with Durvalumab ES-SCLC View

Description: A Phase 3 Open-label Multicenter Randomized Study of Tarlatamab in Combination With Durvalumab vs Durvalumab Alone in Subjects with Extensive-Stage Small-Cell Lung Cancer Following Platinum Etoposide and Durvalumab (DeLLphi-305) (20200041)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 study of Dato-DXd with stage I adenocarcinoma NSCLC (TROPION-Lung12) View

Description: A Phase III Randomised Open-label Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care Following Complete Tumour Resection in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features (TROPION-Lung12) (D926TC00001)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph3 study of Dato-DXd with stage I adenocarcinoma NSCLC (TROPION-Lung12) View

Description: A Phase III Randomised Open-label Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care Following Complete Tumour Resection in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features (TROPION-Lung12) (D926TC00001)

Indication: Lung Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: III

Title: Ph3 study of Dato-DXd with stage I adenocarcinoma NSCLC (TROPION-Lung12) View

Description: A Phase III Randomised Open-label Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care Following Complete Tumour Resection in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features (TROPION-Lung12) (D926TC00001)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: Ph3 study of Dato-DXd with stage I adenocarcinoma NSCLC (TROPION-Lung12) View

Description: A Phase III Randomised Open-label Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care Following Complete Tumour Resection in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features (TROPION-Lung12) (D926TC00001)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 study of Dato-DXd with stage I adenocarcinoma NSCLC (TROPION-Lung12) View

Description: A Phase III Randomised Open-label Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care Following Complete Tumour Resection in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features (TROPION-Lung12) (D926TC00001)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 study of Dato-DXd with stage I adenocarcinoma NSCLC (TROPION-Lung12) View

Description: A Phase III Randomised Open-label Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care Following Complete Tumour Resection in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features (TROPION-Lung12) (D926TC00001)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 study with patients previously treated KRAS G12C-positive advanced or metastastatic NSCLC View

Description: A phase 3 randomized open-label multicenter study evaluating the efficacy and safety of divarasib versus sotorasib or adagrasib in patients with previously treated KRAS G12C-positive advanced or metastatic Non-Small Cell Lung Cancer (BO45217)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 of Ivonescimab vs pembro for patients with NSCLC (HARMONi-7) View

Description: A Randomized Double-blinded Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression(HARMONi-7)(SMT-112-3007)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 of Ivonescimab vs pembro for patients with NSCLC (HARMONi-7) View

Description: A Randomized Double-blinded Multiregional Phase 3 Study of Ivonescimab Versus Pembrolizumab for the First-line Treatment of Metastatic Non-small Cell Lung Cancer in Patients Whose Tumors Demonstrate High PD-L1 Expression(HARMONi-7)(SMT-112-3007)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 Glofitamab (RO7082859) in combo with POLA-R-CHP B-Cell Lymphoma View

Description: A PHASE III MULTICENTER RANDOMIZED OPEN LABEL STUDY COMPARING THE EFFICACY AND SAFETY OF GLOFITAMAB (RO7082859) IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB CYCLOPHOSPHAMIDE DOXORUBICIN AND PREDNISONE (POLA-R-CHP) VERSUS POLA R CHP IN PREVIOUSLY UNTREATED PATIENTS WITH LARGE B-CELL LYMPHOMA (GO44145)

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Study of (EPCORE FL-2) in previously untreated follicular lymphoma View

Description: A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2) (M22-003)

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma View

Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)

Indication: Melanoma

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma View

Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)

Indication: Melanoma

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Study of Fixed Dose Fianlimab + Cemiplimab vs Relatlimab unresectable or met Melanoma View

Description: A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)

Indication: Melanoma

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: III

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC) View

Description: A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 study of Rina-S versus treatment of investigator choice with ovarian cancer View

Description: A Phase 3 Randomized Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigators Choice (IC) in Patients with Platinum Resistant Ovarian Cancer (GCT1184-02)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph3 study of Rina-S versus treatment of investigator choice with ovarian cancer View

Description: A Phase 3 Randomized Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigators Choice (IC) in Patients with Platinum Resistant Ovarian Cancer (GCT1184-02)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: III

Title: Ph3 study of Rina-S versus treatment of investigator choice with ovarian cancer View

Description: A Phase 3 Randomized Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigators Choice (IC) in Patients with Platinum Resistant Ovarian Cancer (GCT1184-02)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 study of Rina-S versus treatment of investigator choice with ovarian cancer View

Description: A Phase 3 Randomized Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigators Choice (IC) in Patients with Platinum Resistant Ovarian Cancer (GCT1184-02)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 study of RMC-6236 in patients with met pancreatic ductal adenocarcinoma (PDAC) View

Description: A Phase 3 Multicenter Open-label Randomized Study of RMC-6236 versus Investigator's Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RMC-6236-302)

Indication: Pancreatic Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 study of RMC-6236 in patients with met pancreatic ductal adenocarcinoma (PDAC) View

Description: A Phase 3 Multicenter Open-label Randomized Study of RMC-6236 versus Investigator's Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) (RMC-6236-302)

Indication: Pancreatic Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Peritoneal Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Peritoneal Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Peritoneal Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Mirv Sora +/-Beva FRa+ Epi Ova FT PPC (GLORIOSA) View

Description: IMGN853-0421: Randomized multicenter open-label Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with folate receptor alpha-high recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 study of MK-5684 versus alternative NHA in mCRPC View

Description: A Phase 3 Randomized Open-label Study of Opevesostat versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) (OMAHA-004) (MK-5684-004)

Indication: Prostate Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 study of MK-5684 versus alternative NHA in mCRPC View

Description: A Phase 3 Randomized Open-label Study of Opevesostat versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA) (OMAHA-004) (MK-5684-004)

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 study of FOLFIRI in participants with metastatic colorectal cancer View

Description: A Randomized Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants with KRAS/NRAS and BFAF Wild-Type Recurrent Unresectable or Metastatic Colorectal Cancer Who Have Received Prior Chemotherapy (61186372COR3002)

Indication: Rectal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Phase IV

Title: Sacral Neuromodulation for Male OverActive Bladder (MOAB) Study

Indication: Bladder Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: IV

Title: Sacral Neuromodulation for Male OverActive Bladder (MOAB) Study

Indication: Bladder Cancer

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Arlington Cancer Center North

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Arlington North Radiation Oncology

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Arlington South

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: IV

Title: STAR Clinical Study to Further Evaluate Trametinib with rare BRAF V600E or met Solid Tumors View

Description: Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors (CDRB436IIC01)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: IV